WEBULL
WebtradeDownload

PolyNovo (ASX:PNV) Shares Confront Premium Valuation After Margin Compression

Simply Wall St · 1d ago

PolyNovo walked into this result as a high expectation stock, trading on a rich P/E of 94.6x and coming off a 30 day gain of about 23%. Yet the shares still closed around A$1.01. The headline from the full year numbers is margin pressure. Net profit margin over the last 12 months sat at 4.9%, compared with 10.3% a year earlier, and a one off A$4.7m hit dragged on earnings. For a medical equipment growth story priced at a premium, that squeeze is what the market is now testing against the longer term thesis.

Love the PolyNovo growth story but concerned about rich valuation and margin pressure? You can benchmark it against list of solid balance sheet and fundamentals stocks (20 results).

FY 2026 Earnings Summary

  • Revenue (FY 2026 vs FY 2025, trailing 12 months): A$149.984m vs. A$128.699m (change reflected in higher reported trailing revenue)
  • Net Income (FY 2026 vs FY 2025, trailing 12 months, excluding extra items): A$7.341m vs. A$13.214m (decline in net earnings, weighed by a one off A$4.7m loss)
  • Basic EPS (FY 2026 vs FY 2025, trailing 12 months): A$0.0106 vs. A$0.01913 (decline in earnings per share)
  • Net Profit Margin (FY 2026 vs prior year, trailing 12 months): 4.9% vs. 10.3% (margin compression reflecting higher costs and the one off A$4.7m loss)

Prefer clean charts over wading through another wall of earnings figures and margin commentary? Get a full visual picture of PolyNovo, including its valuation setup in the company report for PolyNovo.

ASX:PNV Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
ASX:PNV Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

PolyNovo bull case meets operational reality

Bulls argue PolyNovo is building a broader NovoSorb platform with scale manufacturing that should support expanding use cases and healthier margins over time. The latest year shows part of that story playing out on the top line, with trailing revenue of A$149.984m versus A$128.699m. That suggests the commercial footprint is still growing, even as the stock has fallen about 20% over 90 days after a strong 30 day gain. However, the profit engine that is meant to fund this expansion looks under strain. Net profit margin has compressed from 10.3% to 4.9% and net income, excluding extra items, sits at A$7.341m versus A$13.214m. The one off A$4.7m hit explains some of that pressure but not all of it. The bull narrative around operating leverage and margin expansion is not yet backed by the current profitability profile.

Bear case on PolyNovo margin risk tested

Bears focus on regulatory and reimbursement risk, heavy reliance on NovoSorb, and the concern that higher costs and pricing pressure could cap margins even if revenue keeps rising. The current print gives them some support. Net profit margin has moved from 10.3% down to 4.9%, while basic EPS has eased from A$0.01913 to A$0.0106 despite higher trailing revenue. Part of this is the A$4.7m one off loss, which validates fears that execution and one time items can make earnings volatile. The recent 7 day share price move, down about 3%, shows some of that concern persisting after results. At the same time, PolyNovo is still profitable and growing revenue, which challenges the harshest versions of the bear story that assume stalled adoption or a collapse in earnings quality.

Compare PolyNovo’s internal growth story with how the market is actually pricing that risk reward trade off. See the consensus price target analysis for PolyNovo to check whether analysts think the current A$1.005 share price leaves much upside or downside from here.

Stay Ahead With Simply Wall St

If the mix of strong PolyNovo revenue and tighter margins has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry point. After you take a position, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For a longer term view, lean on the Community to see how other investors are thinking through the same risks and opportunities. That way you can spot potential catalysts or warning signs early and stay ahead of the market.

Seeking Alternatives Beyond PolyNovo?

Fresh stock ideas can move fast. Some are already building breakout momentum, others are quietly dropping into bargain territory. Catch the next wave under the radar for now and act now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.